Business opportunity
Scientists at Oslo University Hospital and the University of Oslo (Norway) have developed a novel metastasis-oriented test and companion diagnostic to predict treatment for the subgroup of patients with the poorest survival after a diagnosis with colorectal cancer (CRC) liver metastases.
Inven2 AS seeks partners for co-development or licensing of IP.
Technology description
Gene expression-based subtyping of tumors has the potential to form a new paradigm for stratified treatment of CRC. However, current frameworks are based on the transcriptomic profiles of primary tumors and metastatic tumor heterogeneity is a challenge.
This test, an algorithm based on the expression levels of 9 genes, identifies a clinically relevant subgroup of liver metastases associated with a particularly poor patient survival. The subgroup covers ~18% of all patients with liver metastasis and is defined as the LMS1-group.
In parallel with the test is a collection of patient-derived organoids (PDOs) from liver metastases, screened for sensitivity to a drug library. The PDOs are genotyped and classified in different LMS-groups for discovery of drug sensitivities. For the LMS1 subgroup, a list of novel drugs (for this indication) demonstrates higher treatment activity than the conventional treatment regime.
Advantages
This novel metastasis-oriented test shows great potential for clinically relevant transcriptomic classification of CRCs in the context of metastatic tumor heterogeneity, and the LMS1 mini-classifier is constructed to facilitate prediction of drug sensitivity for further improved clinical treatment.
Publications
https://genomemedicine.biomedcentral.com/counter/pdf/10.1186/s13073-021-00956-1.pdf
IPR
A patent application has been filed.
